How to Avoid a Disastrous Gene-Therapy Price Battle – Bloomberg
Bloomberg |
How to Avoid a Disastrous Gene–Therapy Price Battle
Bloomberg Philadelphia gene–therapy maker Spark Therapeutics Inc. — whose eye-disease drug is likely to be the first such medicine approved for use in the U.S. — generated backlash recently for suggesting such a high price may be justified. As more of these … |
